肝动脉加门静脉灌注化疗在结直肠癌肝转移中的应用

CHEMOTHERAPY VIA HEPATIC ARTERY AND PORTAL VEIN FOR THE PREVENTION OF LIVER METASTASIS OF COLORECTAL CANCER

目的 评价肝动脉加门静脉灌注化疗药物治疗结直肠癌肝转移的临床效果。方法 将 4 8例结直肠癌肝转移患者随机分成 3组 :肝动脉加门静脉灌注化疗 (Ⅰ组 ) 17例 ,肝动脉灌注化疗 (Ⅱ组 ) 16例 ,门静脉灌注化疗 (Ⅲ组 ) 15例。术后 2周开始化疗 ,化疗方案为氟尿嘧啶 (5 FU) 5 0 0mg/m2 +丝裂霉素 (MMC) 4mg/m2 +表阿霉素 (EPI) 6 0mg/m2 ,每周 1次 ,2～ 3次为 1个疗程。 3组化疗方案的剂量、频次均相同。结果 肝转移灶治疗有效率 (CR +PR) :Ⅰ组为 76 5 % ,Ⅱ组为 6 2 5 % ,Ⅲ组为 4 6 7% ,Ⅰ组与Ⅱ、Ⅲ组比较差异有统计学意义 (P <0 0 1) ;患者 0 5、1、2年生存率Ⅰ组为 10 0 %、82 4 %和 5 2 9% ,Ⅱ组为 87 5 %、6 2 5 %和 4 3 7% ,Ⅲ组为93 3%、6 0 %和 33 3% ,Ⅰ组与Ⅱ、Ⅲ组比较差异有统计学意义 (P <0 0 1)。 3组患者均无严重毒副反应及并发症出现。结论 肝动脉加门静脉灌注化疗可使局部药物达较高浓度 ,分布更均匀 ,是治疗和预防结直肠癌肝转移的有效方法 ,其疗效明显优于单纯肝动脉灌注化疗或门静脉灌注化疗。

Objective To evaluate the clinical effect of chemotherapy via both hepatic artery and portal vein on liver metastasis of colorectal cancer. Methods Forty-eight patients with colorectal cancer (admitted to our hospital from Jan, 1994 to Dec, 2000)were divided into group Ⅰ, in which 17 patients received chemotherapy via both hepatic artery and portal vein, group Ⅱ in which 16 patients received simple hepatic artery chemotherapy, and group Ⅲ in which 15 patients received simple portal vein chemotherapy. Chemotherapy was begun 2 weeks after operation. The drugs used in chemotherapy regime were 5-fluorouracil(5-FU) 500mg/m 2 + Mitomycin(MMC) 4mg/m 2 + Epirubicin(EPI) 60mg/m 2, once per week, 2-3 times as a course. The chemotherapy regime was the same for the 3 groups. Results The respective effective rate for liver metastasis was 76.5%, 62.5%, 46.7% in group Ⅰ, group Ⅱ, and group Ⅲ. The 0.5, 1 and 2 year survival rates were 100%, 82.4% and 52.9% respectively in group Ⅰ, 87.5%, 62.5% and 43.7% respectively in group Ⅱ, and 93.3%, 60% and 33.3% respectively in group Ⅲ. There were statistically significant differences between group Ⅰ and groups Ⅱ and Ⅲ (P<0.01). No severe adverse reaction and complications occurred in these 3 groups. Conclusion Chemotherapy via both hepatic artery and portal vein offers an even distribution of the drugs in a higher concentration in the liver, and the clinical results indicate that it is an effective way to prevent liver metastasis from colorectal cancer.